Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $310

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $292 to $310.